EXCLUSIVE: Ex-Abbott marketing director to lead Myconostica's expansion
This article was originally published in Clinica
Executive Summary
Hot on the heels of its first product’s market debut, UK diagnostics company Myconostica has enlisted a new CEO to drive the worldwide commercialisation of its FXG:RESP (Asp+) test for fungal pneumonia-causing pathogens, writes Tina Tan.